Opdivo (nivolumab) has received approvals for two new indications in classical Hodgkin Lymphoma (cHL) from the US Food and ...

Opdivo (nivolumab) has been approved for two new classical Hodgkin lymphoma (cHL) indications in the US and the EU. The US ...

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy ...

These approvals will incite a modest reorganisation in the market of antibody-based therapies for the illness.

Bristol Myers Squibb transforms the classical Hodgkin lymphoma treatment paradigm with expanded US & EMA approvals for Opdivo: Princeton, New Jersey Monday, March 23, 2026, 17:00 ...

Nivolumab plus AVD is now FDA-approved for previously untreated Stage III or IV classical Hodgkin lymphoma in patients aged 12 years and older.

FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...

The University of Arizona Comprehensive Cancer Center has appointed Dr. Rachna Shroff as the inaugural John F. and Valli S.

Dr. Wendy Woodward discussed the transformative rise of hypofractionated radiation. For years, the "daily grind" of breast ...

Dual FDA approvals open Hodgkin lymphoma care options by expanding Opdivo use in pediatric and adult patients with classical ...

The FDA has approved nivolumab (Opdivo) plus AVD as first-line treatment for advanced classical Hodgkin lymphoma in patients ...

First Extensive Analysis of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic ...